Serum concentrations of CA 125, CA 15-3, CA 19-9 and CEA in normal pregnancy: a longitudinal study
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Although cancer diagnosed during pregnancy is rare, the coexistence of pregnancy and malignancy becomes more common in view of prolongation of reproductive age. Therefore, it is important that the specificity of a tumor marker be evaluated during pregnancy to avoid misinterpretation in the follow-up of a pregnant cancer patient. The present study aims to investigate the serum concentrations of CA-125, CA 15-3, CA 19-9 and CEA in healthy pregnant women through gestation.
In this prospective study, we followed thirty healthy pregnant women. Blood samples were obtained during each trimester of pregnancy (10–12, 22–24 and 34–36 weeks). The maternal serum levels of CA-125, CA 15-3, CA 19-9 and CEA were measured using electrochemiluminescence immunoassay.
There was no difference between the first and second trimester serum levels of CA 125, CEA and CA 19-9. However, serum CA 125 levels in third trimester were found to be significantly elevated in pregnants compared to the second trimester (median values 19.6 vs. 15.6 IU/mL, p = 0,009). Similarly, the serum CEA levels in third trimester were significantly higher than those of second trimester (median values 1.1 vs. 0.7 ng/ml, p = 0.001). It is also found that CEA and CA 19-9 assay values were significantly elevated in the third trimester of pregnancy when compared with the first trimester of pregnancy (CEA median values 1.1 vs. 0.7 ng/ml, p = 0.02 and CA 19-9 median values 11.6 vs. 7.7 IU/mL, p = 0,02). Three trimester had statistically similar levels for serum CA 15-3 (median values 17.5, 19.7 and 18.3 U/mL, respectively). The four tumor markers assay values were found generally within the normal range.
These findings suggest that maternal serum levels of CA 125, CEA and CA 19-9 were increased during third trimester of pregnancy. However, these elevations were within the normal range. CA 15-3 is independent of gestation and reliable tumor markers in monitoring malignancy in pregnant patients.
- Sarandakou A, Protonotariou E, Rizos D (2007) Tumor markers in biological fluids associated with pregnancy. Crit Rev Clin Lab Sci 44(2):151–178 CrossRef
- Schlageter MH, Larghero J, Cassinat B, Toubert ME, Borschneck C, Rain JD (1998) Serum Carcinoembryonic Antigen, Cancer Antigen 125, Cancer Antigen 15–3, Squamous Cell Carcinoma, and Tumor-associated Trypsin Inhibitor Concentrations during Healthy Pregnancy. Clin Chem 44(9):1995–1998
- Cheli CD, Morris DL, Neaman IE, Dai J, Allard WJ, Yeung KK (1999) Measurement of four tumor marker antigens in the sera of pregnant women. J Clin Lab Anal 13(1):35–39 CrossRef
- Keinan-Boker L, Lerner-Geva L, Kaufman B, Meirow D (2008) Pregnancy-Associated Breast Cancer. Isr Med Assoc J 10:722–727
- Pentheroudakis G (2008) Cancer and pregnancy. Ann Oncol. 19:38–39 CrossRef
- Høgdall E (2008) Cancer antigen 125 and prognosis. Curr Opin Obstet Gynecol 20:4–8 CrossRef
- Stuırgeon C (2002) Practice guidelines for tumor marker use in the clinic. Clin Chem 48(8):1151–1159
- Duffy MJ (2006) Serum tumor markers in breast cancer: are they of clinical value? Clin Chem 52(3):345–351 CrossRef
- Fry LC, Mönkemüller K, Malfertheiner P (2008) Molecular markers of pancreatic cancer: development and clinical relevance. Langenbecks Arch Surg 393:883–890 CrossRef
- Goonetilleke KS, Siriwardena AK (2007) Systematic review of carbohydrate antigen (CA 19–9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol 33(3):266–270 CrossRef
- Duffy MJ (2001) Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful? Clin Chem 47(4):624–630
- Touitou Y, Darbois Y, Bogdan A, Auzeby A, Keusseoglou S (1989) Tumour marker antigens during menses and pregnancy. Br J Cancer 60(3):419–420 CrossRef
- Bon GG, Kenemans P, Verstraeten AA, Go S, Philipi PA, van Kamp GJ, van Geijn HP, van Vugt JM (2001) Maternal serum Ca125 and Ca15–3 antigen levels in normal and pathological pregnancy. Fetal Diagn 16(3):166–172 CrossRef
- Kobayashi F, Sagawa N, Nakamura K, Nonogaki M, Ban C, Fujii S, Mori T (1989) Mechanism and clinical significance of elevated CA 125 levels in the sera of pregnant women. Am J Obstet Gynecol 160(3):563–566
- Spitzer M, Kaushal N, Benjamin F (1998) Maternal CA-125 levels in pregnancy and the puerperium. J Reprod Med 43(4):387–392
- Botsis D, Sarandakou A, Kassanos D, Kontoravdis A, Rizos D, Protonotariou E, Phocas I, Creatsas G (1999) Breast cancer markers during normal pregnancy. Anticancer Res 19(4C):3539–3541
- Serum concentrations of CA 125, CA 15-3, CA 19-9 and CEA in normal pregnancy: a longitudinal study
Archives of Gynecology and Obstetrics
Volume 285, Issue 3 , pp 579-584
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Tumor markers
- CA 125, CA 15-3
- CA 19-9
- Carcinoembryonic antigen
- Industry Sectors
- Author Affiliations
- 1. Department of Clinical Biochemistry, Dr. Lutfi Kirdar Kartal Education and Research Hospital, Istanbul, Turkey
- 3. Cumhuriyet Mah. Libadiye Cad. Seçkin Sok. Seçkinler Sitesi B Blok D:5 Üskudar, 34696, Istanbul, Turkey
- 2. Department of Obstetrics and Gynecology, Dr. Lutfi Kirdar Kartal Education and Research Hospital, Istanbul, Turkey